Claassens, Daniel M. F. http://orcid.org/0000-0001-6338-2569
van Dorst, Pim W. M.
Vos, Gerrit J. A.
Bergmeijer, Thomas O.
Hermanides, Renicus S.
van ’t Hof, Arnoud W. J.
van der Harst, Pim
Barbato, Emanuele
Morisco, Carmine
Tjon Joe Gin, Richard M.
Asselbergs, Folkert W.
Mosterd, Arend
Herrman, Jean-Paul R.
Dewilde, Willem J. M.
Postma, Maarten J.
Deneer, Vera H. M.
ten Berg, Jurriën M.
Boersma, Cornelis
Clinical trials referenced in this document:
Documents that mention this clinical trial
Precision antiplatelet therapy for the prevention of ischaemic stroke
https://doi.org/10.1136/svn-2021-001383
Cost Effectiveness of a CYP2C19 Genotype-Guided Strategy in Patients with Acute Myocardial Infarction: Results from the POPular Genetics Trial
https://doi.org/10.1007/s40256-021-00496-4
CYP2C19 genotype–guided antiplatelet therapy in ST-segment elevation myocardial infarction patients—Rationale and design of the Patient Outcome after primary PCI (POPular) Genetics study
https://doi.org/10.1016/j.ahj.2014.03.006
Platelet function monitoring to adjust antiplatelet therapy in elderly patients stented for an acute coronary syndrome (ANTARCTIC): an open-label, blinded-endpoint, randomised controlled superiority trial
https://doi.org/10.1016/s0140-6736(16)31323-x
Funding for this research was provided by:
ZonMw (171102022)
Spartan Bioscience
Article History
Accepted: 8 August 2021
First Online: 7 September 2021
Declarations
:
: This work was supported by ZonMw, a Dutch government agency, as part of its efficiency research program (project 171102022). Spartan Bioscience (Nepean, Ottawa, ON, Canada) provided the Spartan RX system and the reagents used free of charge.
: Dr. Asselbergs has received grants from the University College London Hospitals National Institute for Health Research Biomedical Research Centre. Dr. van 't Hof has received institutional grants from Medtronic, AstraZeneca, and Sanofi and personal fees from AstraZeneca and Amgen. Dr. Barbato has received personal fees from Boston Scientific, Abbott Vascular, and GE. Dr. Ten Berg has received institutional grants from AstraZeneca and ZonMw and personal fees from AstraZeneca, Daiichi Sankyo, Eli Lilly, the Medicines Company, Accumetrics, Boehringer-Ingelheim, Bayer, BMS, Pfizer, and Ferrer. Dr. Postma has received institutional grants from AstraZeneca, GSK, Pfizer, and Amgen and personal fees from AstraZeneca, Daiichi Sankyo, Boehringer-Ingelheim, Bayer, BMS, Pfizer, GSK, and Roche. Daniel M.F. Claassens, Pim W.M. van Dorst, Gerrit J.A. Vos, Thomas O. Bergmeijer, Renicus S. Hermanides, Pim van der Harst, Carmine Morisco, Richard M. Tjon Joe Gin, Arend Mosterd, Jean-Paul R. Herrman, Willem J.M. Dewilde, Vera H.M. Deneer, and Cornelis Boersma have no conflicts of interest that are directly relevant to the content of this article.
: Data will be made available upon reasonable request
: Analyses were performed using R version 3.6 or later and Excel.
: An institutional review board at each site approved the trial.
: All patients provided informed consent to participate in the trial.
: Conceptualization: TOB, JMtB, VHMD. Methodology: DMFC, WMvD, CB. Formal analysis and investigation: DMFC, WMvD, TOB, GJAV. Writing—original draft preparation: DMFC, WMvD. Writing—review and editing: GJAV, TOB, RSH, AWJv’tH, PvdH, EB, CM, RMTJG, FWA, AM, JPRH, WJMD, MJP. Funding acquisition: VHMD. Resources: RSH, AWJv’tH, PvdH, EB, CM, RMTJG, FWA, AM, JPRH, WJMD. Supervision: VHMD, JMtB, CB, MJP.